Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

【作者(必填)】Wolchok JD[size=0.8461em]1, Chiarion-Sileni V[size=0.8461em]1, Gonzalez R[size=0.8461em]1, Rutkowski P[size=0.8461em]1, Grob JJ[size=0.8461em]1, Cowey CL[size=0.8461em]1, Lao CD[size=0.8461em]1, Wagstaff J[size=0.8461em]1, Schadendorf D[size=0.8461em]1, Ferrucci PF[size=0.8461em]1, Smylie M[size=0.8461em]1,Dummer R[size=0.8461em]1, Hill A[size=0.8461em]1, Hogg D[size=0.8461em]1, Haanen J[size=0.8461em]1, Carlino MS[size=0.8461em]1, Bechter O[size=0.8461em]1, Maio M[size=0.8461em]1, Marquez-Rodas I[size=0.8461em]1, Guidoboni M[size=0.8461em]1, McArthur G[size=0.8461em]1, Lebbé C[size=0.8461em]1, Ascierto PA[size=0.8461em]1,Long GV[size=0.8461em]1, Cebon J[size=0.8461em]1, Sosman J[size=0.8461em]1, Postow MA[size=0.8461em]1, Callahan MK[size=0.8461em]1, Walker D[size=0.8461em]1, Rollin L[size=0.8461em]1, Bhore R[size=0.8461em]1, Hodi FS[size=0.8461em]1, Larkin J[size=0.8461em]1.

【文题(必填)】[size=1.4em]Overall [size=1.4em]Survival[size=1.4em] [size=1.4em]with[size=1.4em] [size=1.4em]Combined[size=1.4em] [size=1.4em]Nivolumab[size=1.4em] [size=1.4em]and[size=1.4em] [size=1.4em]Ipilimumab[size=1.4em] [size=1.4em]in[size=1.4em] [size=1.4em]Advanced[size=1.4em] [size=1.4em]Melanoma[size=1.4em].

【年份(必填)】2017

【全文链接或数据库名称(选填)】https://www.ncbi.nlm.nih.gov/pubmed/28889792